{"id":1209,"date":"2025-11-10T20:00:57","date_gmt":"2025-11-10T20:00:57","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/"},"modified":"2026-05-06T14:01:31","modified_gmt":"2026-05-06T14:01:31","slug":"slu-pp-332-vs-o-304-exercise-mimetic-comparison","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/","title":{"rendered":"SLU-PP-332 vs O-304: Exercise Mimetic Comparison"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav>\n<ul class='ez-toc-list ez-toc-list-level-1 ' >\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\" >SLU-PP-332 vs O-304: Exercise Mimetic Comparison<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_and_O-304_Introduction\" >SLU-PP-332 and O-304 Introduction<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Molecular_Structure_and_Chemical_Data_Comparison\" >Molecular Structure and Chemical Data Comparison<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Research_Areas\" >SLU-PP-332 vs O-304 Research Areas<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Mechanism_of_Action_SLU-PP-332_vs_O-304\" >Mechanism of Action: SLU-PP-332 vs O-304<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Clinical_Research_and_Study_Results_Comparison\" >Clinical Research and Study Results Comparison<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Future_Research_Directions_for_Both_Compounds\" >Future Research Directions for Both Compounds<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Availability_and_Access_SLU-PP-332_vs_O-304\" >Availability and Access: SLU-PP-332 vs O-304<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Summary_and_Conclusion\" >Summary and Conclusion<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#References\" >References<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Molecular_Structure_and_Chemical_Data_Comparison-2\" >Molecular Structure and Chemical Data Comparison<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Research_Areas-2\" >SLU-PP-332 vs O-304 Research Areas<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Mechanism_of_Action_SLU-PP-332_vs_O-304-2\" >Mechanism of Action: SLU-PP-332 vs O-304<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Clinical_Research_and_Study_Results_Comparison-2\" >Clinical Research and Study Results Comparison<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Future_Research_Directions_for_Both_Compounds-2\" >Future Research Directions for Both Compounds<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Availability_and_Access_SLU-PP-332_vs_O-304-2\" >Availability and Access: SLU-PP-332 vs O-304<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Summary_and_Conclusion-2\" >Summary and Conclusion<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#References-2\" >References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><a rel=\"noopener noreferrer\" href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" target=\"_self\">SLU-PP-332<\/a> vs O-304: Exercise Mimetic Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span>SLU-PP-332 and O-304 Introduction<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a rel=\"noopener noreferrer\" href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" target=\"_self\">SLU-PP-332<\/a> is a <strong>synthetic ERR\u03b1<\/strong> agonist that <strong>mimics exercise<\/strong> at the cellular level, O-304 is a different class of metabolic modulators targeting different pathways. Both are <strong>exercise mimetics<\/strong> &#8211; <strong>experimental therapeutics<\/strong> that replicate the benefits of <strong>exercise<\/strong> without actual <strong>aerobic exercise<\/strong>.<\/p>\n<p>These compounds address the gaps in treating <strong>metabolic diseases<\/strong>, <strong>obesity<\/strong> and <strong>metabolic syndrome<\/strong> for populations that can\u2019t exercise. SLU-PP-332 works through <strong>estrogen related receptors<\/strong> activation, specifically ERR\u03b1, O-304 through AMPK activation pathways, but As of available research data, O-304 (also known as <strong>ATX-304<\/strong>, developed by Amplifier Therapeutics) has progressed to Phase IIa human clinical trials, while <strong>SLU-PP-332<\/strong> remains in preclinical research stages with no published human trial data.<\/p>\n<p>The comparison between these <strong>exercise mimetics<\/strong> is relevant for researchers and clinicians looking for alternatives to <strong>increase physical activity<\/strong> in patients with <strong>chronic diseases<\/strong>, <strong>heart failure<\/strong> or mobility limitations.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span>Molecular Structure and Chemical Data Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a rel=\"noopener noreferrer\" href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" target=\"_self\"><strong>SLU-PP-332<\/strong><\/a> is a small molecule <strong>synthetic ERR\u03b1<\/strong> agonist developed at <strong>Louis University<\/strong>, research published in <strong>ACS Chem Biol<\/strong> shows its potent activation of <strong>estrogen related receptors<\/strong>. The compound has good oral bioavailability, suitable for research use.<\/p>\n<p>O-304 (clinically designated <strong>ATX-304<\/strong> by its developer <strong>Amplifier Therapeutics<\/strong>) is a pan-AMPK activator with a characterized salt formulation. Both compounds target <strong>energy metabolism<\/strong> pathways but differ in chemical structure and upstream signaling: SLU-PP-332 acts at the transcription factor level (nuclear ERR activation), while O-304 works via enzyme signaling (cytoplasmic AMPK activation).<\/p>\n<p><a rel=\"noopener noreferrer\" href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" target=\"_self\"><strong>SLU-PP-332<\/strong><\/a> is stable under normal lab conditions and has consistent pharmacokinetic profile in preclinical studies. The compound <strong>fat oxidation<\/strong> is through direct <strong>estrogen related receptors<\/strong> activation, has sustained effect on <strong>whole body metabolism<\/strong>.<\/p>\n<p>Bioavailability profiles suggest both compounds can be orally administered, but <strong>more research<\/strong> is needed to determine optimal dosing and delivery for each <strong>exercise mimetic<\/strong>.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span>SLU-PP-332 vs O-304 Research Areas<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>slu pp 332<\/strong> research has focused on <strong>diet induced obesity<\/strong> models where the compound shows impressive <strong>body weight<\/strong> loss and <strong>fat metabolism<\/strong> improvement. Studies in <strong>obese mice<\/strong> show <strong>pp 332<\/strong> reduces <strong>fat accumulation<\/strong> and increases <strong>energy expenditure<\/strong> without affecting <strong>food intake<\/strong>.<\/p>\n<p><strong>Metabolic syndrome<\/strong> is a key area for both compounds, <strong>slu pp<\/strong> has shown promise in addressing <strong>insulin resistance<\/strong> and <strong>hepatic steatosis<\/strong>. The compound\u2019s ability to increase <strong>fatty acid oxidation<\/strong> and <strong>insulin sensitivity<\/strong> makes it a potential therapeutic for type 2 diabetes and related <strong>metabolic diseases<\/strong>.<\/p>\n<p><strong>Mitochondrial function<\/strong> studies show <strong>slu pp 332<\/strong> promotes <strong>mitochondrial biogenesis<\/strong> and improves <strong>cellular respiration<\/strong> in <strong>skeletal muscle<\/strong> tissue. This <strong>key regulator<\/strong> affects <strong>adipose tissue<\/strong> composition, converts <strong>white adipose tissue<\/strong> to a more metabolically active phenotype.<\/p>\n<p>Anti-aging research is emerging as an area of interest, both compounds show potential to address <strong>mitochondrial dysfunction<\/strong> associated with <strong>aging<\/strong>. The compounds\u2019 effect on <strong>metabolic flexibility<\/strong> may contribute to longevity pathways and age-related disease prevention.<\/p>\n<p><strong>Cardiovascular Safety \u2014 Resting Heart Rate:<\/strong> Preclinical research in mice has identified a notable finding with SLU-PP-332: the compound produced a measurable increase in <strong>resting heart rate<\/strong>. This cardiovascular signal is considered a significant research variable for ERR agonists and represents an area requiring further investigation before human trial applications can be considered. No equivalent cardiovascular signal has been reported in O-304 (ATX-304) Phase IIa trial data.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span>Mechanism of Action: SLU-PP-332 vs O-304<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>SLU-PP-332<\/strong> works through a complex <strong>estrogen related receptors<\/strong> activation pathway, targeting ERR\u03b1 to trigger a comprehensive <strong>metabolic<\/strong> reprogramming. This activation stimulates PGC-1\u03b1, a <strong>critical player<\/strong> in <strong>mitochondrial biogenesis<\/strong>, and upregulates GLUT4 <strong>expression<\/strong> for increased <strong>glucose<\/strong> uptake in <strong>muscle<\/strong> tissue.<\/p>\n<p>The compound\u2019s mechanism <strong>increases exercise capacity<\/strong> by promoting <strong>fatty acid oxidation<\/strong> enzymes and increasing <strong>energy expenditure<\/strong> at the <strong>cellular level<\/strong>. This converts <strong>muscles<\/strong> to an oxidative phenotype, similar to what is seen with <strong>aerobic training<\/strong>.<\/p>\n<p>O-304 mechanism targets AMPK pathways, a different approach to <strong>metabolic regulation<\/strong>. Both compounds increase <strong>fat metabolism<\/strong> and <strong>energy<\/strong> utilization but their upstream signaling cascades are very different in their molecular targets and downstream effects.<strong>SLU-PP-332<\/strong> mechanism specifically upregulates the genes <strong>Pdk4<\/strong> (pyruvate dehydrogenase kinase 4), <strong>Glut4<\/strong>, and <strong>DDIT4<\/strong>, directly affecting substrate selection and glucose homeostasis in <strong>muscle<\/strong> cells. O-304 activates AMPK through a distinct mechanism: it suppresses <strong>Thr172 dephosphorylation<\/strong>, keeping AMPK in an active phosphorylated state and sustaining metabolic activation. Both targeted approaches increase <strong>energy expenditure<\/strong> without the typical increase in <strong>appetite<\/strong> seen with other <strong>metabolic<\/strong> interventions.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span>Clinical Research and Study Results Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Preclinical studies on <strong>slu pp 332<\/strong> have shown impressive results in <strong>obese mice<\/strong>, with significant improvements in <strong>endurance<\/strong>, <strong>exercise capacity<\/strong> and overall <strong>metabolic health<\/strong>. Research by <strong>Billon C<\/strong> and colleagues showed the compound induces <strong>fat loss<\/strong> and improves <strong>mitochondrial function<\/strong> without adverse effects on <strong>liver<\/strong> function or general health parameters.<\/p>\n<p><strong>SLU-PP-332<\/strong> studies show <strong>improved endurance<\/strong> performance, increased VO\u2082 max and enhanced <strong>fatty acids<\/strong> oxidation in animal models. The compound affects <strong>body composition<\/strong> by reducing <strong>fat storage<\/strong> and improving <strong>metabolic flexibility<\/strong>, relevant for <strong>diabetes<\/strong> prevention and management.<\/p>\n<p>Safety profile of <strong>slu pp 332<\/strong> looks good in preclinical studies with no significant adverse effects in <strong>mice<\/strong> models. The compound has a clean side effect profile compared to some other <strong>exercise mimetics<\/strong> that may have cardiovascular or neurological side effects.<\/p>\n<p>O-304 research data is limited in the literature, more research is needed to establish efficacy and safety profiles. Comparative studies between these compounds are required to determine advantages for specific therapeutic applications.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span>Future Research Directions for Both Compounds<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>SLU-PP-332<\/strong> is moving towards human clinical trials, investigators are focusing on dose optimization and long term safety. The compound\u2019s potential as <strong>FDA approved<\/strong> therapeutic depends on successful translation from animal models to human subjects with <strong>metabolic syndrome<\/strong> and related conditions.<\/p>\n<p>Combination therapy studies are emerging, particularly on how <strong>slu pp 332<\/strong> can complement existing <strong>diabetes<\/strong> treatments or lifestyle interventions. Research on the compound\u2019s effects on <strong>aging<\/strong> and age-related <strong>metabolic diseases<\/strong> is <a rel=\"noopener noreferrer\" href=\"http:\/\/expanding.New\" target=\"_self\">expanding.New<\/a> class <strong>exercise mimetics<\/strong> based on <strong>estrogen related receptors<\/strong> activation may lead to better formulations with improved bioavailability and tissue specificity. Long term effects on <strong>mitochondrial function<\/strong> and <strong>cellular respiration<\/strong> need to be investigated.<\/p>\n<p>Regulatory pathways for both compounds need to be considered as <strong>experimental therapeutics<\/strong>. The risk of misuse as performance-enhancing agents requires appropriate regulatory framework for clinical development and therapeutic use.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span>Availability and Access: SLU-PP-332 vs O-304<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Both <strong>slu pp 332<\/strong> and O-304 are in research phase and not <strong>FDA approved<\/strong> for clinical use. Access is limited to research institutions and qualified investigators conducting research on <strong>exercise mimetics<\/strong> and <strong>metabolic<\/strong> health interventions.<\/p>\n<p><strong>SLU-PP-332<\/strong> is available through research peptide suppliers but requires quality verification and compliance with institutional research protocols. The compound is an investigational <strong>drug<\/strong> and requires proper oversight and adherence to research ethics guidelines.<\/p>\n<p>Regulatory classification of these <strong>exercise mimetics<\/strong> vary by country, most countries require research-only use under institutional supervision. <strong>Side effects<\/strong> and long term safety profile are under investigation and not available for broader access.<\/p>\n<p>Cost for research use depends on compound complexity and synthesis requirements. As research progresses and manufacturing scales up, availability and cost may improve for qualified research applications.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span>Summary and Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>SLU-PP-332<\/strong> is a well characterized <strong>exercise mimetic<\/strong> with robust preclinical data supporting its use for <strong>metabolic diseases<\/strong>, <strong>obesity<\/strong> and <strong>diabetes<\/strong>. Its mechanism through <strong>estrogen related receptors<\/strong> activation is a unique way to increase <strong>energy metabolism<\/strong> and <strong>fat oxidation<\/strong> without actual <strong>exercise<\/strong>.<\/p>\n<p>The compound <strong>mimics exercise<\/strong> at the <strong>cellular level<\/strong> and improves <strong>mitochondrial function<\/strong> and <strong>metabolic flexibility<\/strong> making it a promising therapeutic candidate. Studies in <strong>obese mice<\/strong> show significant benefits for <strong>body weight<\/strong>, <strong>fat metabolism<\/strong> and overall <strong>metabolic health<\/strong>.<\/p>\n<p>O-304 is another approach through AMPK activation but limited research data makes comparison challenging. <strong>More research<\/strong> is needed to fully characterize O-304\u2019s therapeutic potential and safety profile vs <strong>slu pp 332<\/strong>.For researchers and clinicians interested in <strong>exercise mimetics<\/strong>, <strong>SLU-PP-332<\/strong> has the most data available, but both compounds need more development before clinical use.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul class=\"wp-block-list\">\n<li>Billon C, et al. <strong>ACS Chem Biol<\/strong>. 2023. <strong>SLU-PP-332<\/strong> activation of <strong>estrogen related receptors<\/strong> for <strong>metabolic<\/strong> gain.<\/li>\n<li><strong>Welch R<\/strong>, <strong>Banerjee S<\/strong>, et al. Preclinical studies of <strong>slu pp 332<\/strong> in <strong>diet induced obesity<\/strong> models.<\/li>\n<li>Xu et al. 2023. <strong>Mitochondrial biogenesis<\/strong> and <strong>exercise mimetic<\/strong> effects of <strong>pp 332<\/strong>.<\/li>\n<li>Clinical trial databases for <strong>exercise mimetics<\/strong> research and safety studies.<\/li>\n<li>Regulatory documents for <strong>experimental therapeutics<\/strong> classification and development pathway for <strong>metabolic<\/strong> interventions. and O-304 Introduction<\/li>\n<\/ul>\n<p>SLU-PP-332 is a synthetic ERR\u03b1 agonist that mimics exercise at the cellular level, O-304 is a different class of metabolic modulators targeting different pathways. Both are exercise mimetics\u2014experimental therapeutics that replicate the benefits of exercise without actual aerobic exercise.<\/p>\n<p>These compounds address the gaps in treating metabolic diseases, obesity and metabolic syndrome for populations that can\u2019t exercise. SLU-PP-332 works through estrogen-related receptors activation, specifically ERR\u03b1, O-304 through AMPK activation pathways, but O-304 (ATX-304) has progressed further in clinical development than SLU-PP-332, having completed Phase IIa human trials while SLU-PP-332 remains in preclinical research stages.<\/p>\n<p>The comparison between these exercise mimetics is relevant for researchers and clinicians looking for alternatives to increase physical activity in patients with chronic diseases, heart failure or mobility limitations.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Table of Contents Toggle SLU-PP-332 vs O-304: Exercise Mimetic Comparison SLU-PP-332 and O-304 Introduction Molecular Structure and Chemical Data Comparison SLU-PP-332 vs O-304 Research Areas Mechanism of Action: SLU-PP-332 vs O-304 Clinical Research and Study Results Comparison Future Research Directions for Both Compounds Availability and Access: SLU-PP-332 vs O-304 Summary and Conclusion References Molecular Structure [&#8230;]\n","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-liquids"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1209"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1209\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}